These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Sequential methotrexate and 5-fluorouracil].
    Author: Sasaki T.
    Journal: Gan To Kagaku Ryoho; 1996 Dec; 23(14):1907-10. PubMed ID: 8978795.
    Abstract:
    There are two purported biochemical mechanisms to explain the sequence-dependent synergy between methotrexate (MTX) and 5-fluorouracil (5-FU). One hypothesis is to increase incorporation of FU-TP into RNA and another is more sustained inhibition of DNA synthesis. Clinical studies on MTX.5-FU, significantly higher response rates and longer survival have been reported in gastric and colorectal cancer, especially high dose MTX.5-FU and adriamycin (FAMTX) in gastric cancer. An optimal schedule for treatment has not yet been found. Reviewing data from the literature, a one-3 hour interval between the two drugs in gastric cancer and 3-8 hours in colorectal cancer seems to obtain better results. Sequential MTX.5-FU seems to be a very promising combination.
    [Abstract] [Full Text] [Related] [New Search]